Results 291 to 300 of about 249,430 (314)

Evaluation of total intravenous anesthesia with propofol-guaifenesin-medetomidine and alfaxalone-guaifenesin-medetomidine in Thoroughbred horses undergoing castration

, 2017
Motoki Aoki, Ai Wakuno, Asuka Kushiro, Naomi Mae, Masashi Kakizaki, Shun-ichi NAGATA, Minoru Ohta   +6 more
openalex   +2 more sources

Expert Perspective: Diagnostic Approach to Differentiating Juvenile Dermatomyositis From Muscular Dystrophy

Arthritis &Rheumatology, EarlyView.
Clinical tools that can aid in the diagnostic differentiation of juvenile dermatomyositis from muscular dystrophy.
Jacqueline A. Madison, Sean P. Ferris, Marianne Kerski, Grace Hile, Sophia Matossian, Cara Komisar, Peter J. Strouse, Elizabeth Ames, Erin Neil Knierbein, Jessica L. Turnier   +9 more
wiley   +1 more source

Role of STING Deficiency in Amelioration of Mouse Models of Lupus and Atherosclerosis

Arthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is a systemic autoimmune syndrome characterized by autoreactive responses to nucleic acids, dysregulation of the type I interferon (IFN‐I) pathway, and accelerated atherosclerosis. The stimulator of IFN genes (STING), a cytosolic DNA sensor, has pathogenic implications in various inflammatory diseases ...
Yudong Liu, Carmelo Carmona‐Rivera, Nickie L. Seto, Christopher B. Oliveira, Eduardo Patino‐Martinez, Yvonne Baumer, Tiffany M. Powell‐Wiley, Nehal Mehta, Sarfaraz Hasni, Xuan Zhang, Mariana J. Kaplan   +10 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks. Methods In this randomized, double‐blind, placebo‐controlled phase III trial, patients with treatment‐refractory IIM received SC abatacept (at 125 mg weekly)
Rohit Aggarwal, Ingrid E. Lundberg, Yeong‐Wook Song, Aziz Shaibani, Victoria P. Werth, Michael A. Maldonado   +5 more
wiley   +1 more source

Comparison of patient-controlled analgesia and sedation (PCAS) with remifentanil and propofol versus total intravenous anesthesia (TIVA) with midazolam, fentanyl, and propofol for colonoscopy. [PDF]

Medicine (Baltimore)
Song HY, Shen LJ, Sun W, Zhang LD, Liang JG, Zhang GX, Lu XQ.   +6 more
europepmc   +1 more source

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long‐Term Outcomes in a Prospective, Single‐Arm Trial

Arthritis &Rheumatology, EarlyView.
Objective Two randomized trials for patients with diffuse systemic sclerosis (SSc) demonstrated an overall survival (OS) and event‐free survival (EFS) advantage of autologous hematopoietic stem cell transplantation (AHSCT) using CD34+ selected peripheral blood stem cells (PBSCs) compared with monthly cyclophosphamide (CY).
George E. Georges, Dinesh Khanna, Mark H. Wener, Matthew G. Mei, Maureen D. Mayes, Robert W. Simms, Vaishali Sanchorawala, Chitra Hosing, Suzanne Kafaja, Attaphol Pawarode, Leona A. Holmberg, Jason Kolfenbach, Daniel E. Furst, Keith M. Sullivan, Suiyuan Huang, Ted Gooley, Richard A. Nash   +16 more
wiley   +1 more source

Efficacy of a Tumor Necrosis Factor Inhibitor in Chronic Low‐Back Pain With Modic Type 1 Changes: A Randomized Controlled Trial

Arthritis &Rheumatology, EarlyView.
Efficacy of a Tumor necrosis inhibitor in chronic low‐back pain with Modic type 1 changes: The BackToBasic study, A randomized controlled trial. Objective The efficacy of tumor necrosis factor inhibitors for treating chronic low‐back pain with Modic changes is uncertain.
Elisabeth Gjefsen, Lars C. Bråten, Erica Ponzi, Magnhild H. Dagestad, Gunn H. Marchand, Thomas Kadar, Gunnstein Bakland, Anne J. Haugen, Fredrik Granviken, Tonje W. Flørenes, Nils Vetti, Lars Grøvle, Aksel T. Nilsen, Astrid Lunestad, Thor E. Holmgard, Morten Valberg, Nils Bolstad, Ansgar Espeland, Jens I. Brox, Guro L. Goll, Kjersti Storheim, John‐Anker Zwart   +21 more
wiley   +1 more source

Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To assess the value of serum type I interferon (IFN) score in predicting clinically meaningful progression in limited cutaneous systemic sclerosis (lcSSc) using a novel composite endpoint adopted from the MINIMISE clinical trial. Methods A retrospective, longitudinal lcSSc cohort was identified within a national, multicenter observational ...
Stefano Di Donato, Rebecca Ross, Ranjitha Karanth, Vishal Kakkar, Enrico De Lorenzis, Lesley‐Anne Bissell, Kristina Clark, Philip Yee, Christopher P. Denton, Francesco Del Galdo   +9 more
wiley   +1 more source

Quality of Postoperative Recovery in Total Intravenous Anesthesia between Remimazolam and Propofol for Intraoperative Neurophysiological Monitoring: A Prospective Double-Blind Randomized Controlled Trial. [PDF]

J Pers Med
Lee J, Han DW, Song Y, Lee J, Jeon S, Kim MH.   +5 more
europepmc   +1 more source

Sustained IFN Signature Suppression with Anifrolumab in a SAVI patient Refractory to JAK Inhibitor and Dazukibart Therapy

Arthritis &Rheumatology, Accepted Article.
Objective To report the efficacy and safety of interferon‐β (IFNβ) neutralizing monoclonal antibody (dazukibart), followed by treatment with anti‐IFNAR1 antibody (anifrolumab), in a patient with STING‐associated vasculopathy with onset in infancy (SAVI) who had vasculitic ulcers and systemic inflammation refractory to Janus kinase inhibition (JAKi ...
Sara Alehashemi, Bjoern Buehring, Adriana A de Jesus, Sachin Gaurav, Andre Rastegar, Alexi Baumgardner, Kip Friend, Oluwatobi T. Arisa, William D. Figg, Danielle Fink, Douglas B. Kuhns, Ben Colton, Cody J Peer, Raphaela Goldbach‐Mansky   +13 more
wiley   +1 more source